A strong and low-stiffness bio-compatible titanium alloy
The titanium-based alloy composition, optimized through the 'Alloys-By-Design' method, addresses the balance of strength and bio-compatibility in biomedical applications by using specific elemental ratios, achieving enhanced strength and bio-compatibility while reducing stiffness and manufacturability issues.
Patent Information
- Application Number
- PCT/GB2024/051217
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-10
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-14
AI Technical Summary
Current titanium-based alloys for biomedical applications lack a balance between strength and bio-compatibility, often exhibiting modest strength and high stiffness, with limitations in manufacturability and microstructure stability, which can lead to segregation issues during processing.
A titanium-based alloy composition with specific weight percentages of elements like niobium, molybdenum, zirconium, tin, and tantalum, optimized to achieve improved strength, bio-compatibility, and reduced stiffness, using a computational 'Alloys-By-Design' method to ensure homogeneity and manufacturability, while maintaining beta stability and superelasticity.
The alloy achieves enhanced strength, bio-compatibility, and reduced stiffness, with improved manufacturability and processability, minimizing segregation and ensuring a stable microstructure, thus suitable for biomedical applications such as prosthetic devices and implants.
Smart Images

Figure GB2024051217_14112024_PF_FP_ABST
Abstract
Description
[0001] A strong and low-stiffness bio-compatible titanium alloy The present invention relates to titanium-based alloy compositions designed for significantly increased tensile and compressive strength and which has a significantly improved bio-compatibility than current alloys, as well as an improved microstructure for strength and toughness. Moreover, the alloy must exhibit a formability window – in terms of solidification range and microstructure stability. The stiffness of the alloy at operative conditions has also been weighted in the design process of the new alloy. WO2019 / 166749 disclosed bio-compatible titanium alloys for additive manufacturing which are optimised for manufacturability, but which exhibit modest levels of strength. Examples of typical compositions of Ti-alloys which could be used for the manufacture of bio-medical components are listed in Table 1. Alloy IDs 1, 2, 4, 6, 19, 21- 23, 25 are from WO2017 / 137671; IDs 5, 9, 12, 24, 26, 27 are from JP10- 219375; ID 7 is from US4,040,129; IDs 10, 28, 29 are from CN103127558; IDs 11, 13 - 18 are from JP2000-102602; and IDs 3, 8, 9, 20, 30 are from WO2019 / 166749.
[0002] Table 1: Nominal composition in wt.% of prior art titanium alloys. It is an aim of the invention to provide an alloy suitable for biomedical applications preferably which has improved strength in comparison with the titanium alloys listed in Table 1 and low level of stiffness due to the targeted phase architecture – low martensitic start temperature and good beta stability, but not low enough to suppress ‘superelastic’ behaviour. Preferably, the alloy will have an improved bio-compatibility (by including mainly elements which are inert, and which promote bone growth) and / or an improved manufacturability and processability (by comparison of the transient solidification behaviour and the phase architecture in order to reduce the risk of segregation during alloy processing). A lower segregation will translate into a more homogenous chemistry at the micro level. The present invention provides a titanium-based alloy composition consisting in weight percent, of: 0.0 to 22.5 % niobium, 0.0 to 5.0 % molybdenum, 0.0 to 15.0% tantalum, 0 to 22.0% zirconium, 0 to 20.0% tin, 0.0 to 0.5% hafnium, 0.0 to 0.5 % aluminium, 0.0 to 0.5 % vanadium, 0.0 to 0.5 % iron, 0.0 to 0.5 % chromium, 0.0 to 0.5% cobalt, 0.0 to 0.5 % nickel, 0.0 to 1.0% silicon, 0.0 to 0.2% boron, 0.0 to 0.5% calcium, 0.0 to 0.5% carbon, 0.0 to 0.5% manganese, 0.0 to 0.5% gold, 0.0 to 0.5% silver, 0.0 to 0.5% oxygen, 0.0 to 0.5% hydrogen, 0.0 to 0.5% nitrogen, 0.0 to 0.5% palladium, 0.0 to 0.5% lanthanum, the balance being titanium and incidental impurities, wherein the composition satisfies the following equations: ^ ^ ଷ Sn wt. % +^Zr wt. % > 3.5 , and; 3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % Nb wt. % 3.5 +9+14+20+25+27+43 +Ta wt. %Zr wt. % Al wt. % 75 +90−18^ > 2.0in which Fe, Cr, Mo, V, W, Al, Nb, Ta, Zr and Sn represent the amounts of iron, chromium, molybdenum, vanadium, tungsten, aluminium, niobium, tantalum, zirconium and tin in wt% respectively. Such an alloy provides a good balance between biocompatibility and strength without too high a stiffness. In an embodiment, the titanium-based alloy composition consists of 3.0% or less molybdenum, more preferably 1.0 or less molybdenum. Such an alloy has superior biocompatibility. In an embodiment, the titanium-based alloy composition consists of 19.0% or less tin, preferably 18.0% or less tin, preferably 17.0% or less tin, preferably 16.0% or less tin, more preferably 15.0% or less tin, most preferably 13.0% or less. Such an alloy has lower brittleness. In an embodiment, the titanium-based alloy composition consists of 1.0% or more tin, preferably 2.0% or more tin, more preferably 3.0 or 3.5% or more tin, more preferably 5.0% or more tin. Such an alloy has reduced stiffness and increased strength. In an embodiment, the titanium-based alloy composition consists of 20.0% or less zirconium, preferably 18.0% or less zirconium, more preferably 16.0% or less zirconium, even more preferably 15.0% or less zirconium. Such an alloy has superior elongation. In an embodiment, the titanium-based alloy composition consists of 1.5% or more zirconium, preferably 3.0% or more zirconium, more preferably 4.5% or more zirconium. Such an alloy has increased strength and biocompatibility. In an embodiment, the titanium-based alloy composition satisfies the flowing relationship 1 1 3Sn wt. % +6Zr wt. % > 4.0preferably 1 1 3Sn wt. % +6Zr wt. % > 4.5more preferably 1 1 3 Sn wt. % + 6Zr wt. % > 5.0in which Al, Sn and Zr represent the amounts of aluminium, tin and zirconium in wt% respectively. Such alloys have increased strength. In an embodiment, the titanium-based alloy composition consists of 1.5% or more niobium, preferably 2.0% or more niobium, more preferably 3.0% or more niobium, most preferably 5.5% or more niobium. Such an alloy has increases bone compatibility, higher iron equivalence (thus higher beta-stability), and lower martensite start temperature. In an embodiment, the titanium-based alloy composition consists of 20.0% or less niobium, preferably 19.5% or less niobium, preferably 19.0% or less niobium, preferably 17.5% or less niobium, more preferably 16.5% or less niobium. Such an alloy enables other alloying element more potent at increasing strength to be present and thereby meet the iron equivalent, martensite start temperature and bio compatibility targets. In an embodiment, the titanium-based alloy composition consists of 13.5% or less tantalum, preferably 12.0% or less tantalum, more preferably 10.5% or less tantalum. Such an alloy is more easily manufactured and has higher strength. In an embodiment, the titanium-based alloy composition consists of 1.0% or more tantalum, preferably 2.0% or more tantalum, more preferably 2.5% or more tantalum. Such an alloy has improved elasticity and bio compatibility. In an embodiment, the titanium-based alloy composition satisfies the flowing equation 200 < 14.7 ∗ ^^ ^^ + 0.28 ∗ ^^ ^^ ∗ ^^ ^^ + 1.2 ∗ ^^ ^^^2 + 0.14 ∗ ^^ ^^^2 − 225 − 8.88 ∗ ^^ ^^ − 0.68 ∗ ^^ ^^ ∗ ^^ ^^ − 0.0058 ∗ ^^ ^^ ∗ ^^ ^^^2 preferably 250 < 14.7 ∗ ^^ ^^ + 0.28 ∗ ^^ ^^ ∗ ^^ ^^ + 1.2 ∗ ^^ ^^^2 + 0.14 ∗ ^^ ^^^2 − 225 − 8.88 ∗ ^^ ^^ − 0.68 ∗ ^^ ^^ ∗ ^^ ^^ − 0.0058 ∗ ^^ ^^ ∗ ^^ ^^^2, more preferably 300 < 14.7 ∗ ^^ ^^ + 0.28 ∗ ^^ ^^ ∗ ^^ ^^ + 1.2 ∗ ^^ ^^^2 + 0.14 ∗ ^^ ^^^2 − 225 − 8.88 ∗ ^^ ^^ − 0.68 ∗ ^^ ^^ ∗ ^^ ^^ − 0.0058 ∗ ^^ ^^ ∗ ^^ ^^^2, in which Fe, Cr, Mo, V, Nb, Ta, Zr, Sn and Al represent the amounts of iron, chromium, molybdenum, vanadium, niobium, tantalum, zirconium, tin and aluminium in wt% respectively. Such an alloy has reduced stiffness. In an embodiment, the titanium-based alloy composition of any of claims 1 to 12, which satisfies the flowing equation 14.7*Ti + 0.28*Nb*Sn+1.2*Sn^2+0.14*Zr^2-225-8.88*Nb-0.68*Sn*Ti- 0.0058*Zr*Nb^2<450 more preferably 14.7*Ti + 0.28*Nb*Sn+1.2*Sn^2+0.14*Zr^2-225-8.88*Nb-0.68*Sn*Ti- 0.0058*Zr*Nb^2<350 in which Fe, Cr, Mo, V, Nb, Ta, Zr, Sn and Al represent the amounts of iron, chromium, molybdenum, vanadium, niobium, tantalum, zirconium, tin and aluminium in wt% respectively. Such an alloy has a lower effective elastic modulus. In an embodiment, the titanium-based alloy composition of any of claims 1 to 13, consisting of 50.0 wt% or more titanium preferably 52.5 wt% or more titanium, more preferably 55.0 wt% or more titanium. Feedstock of such an alloy is easier to produce with good chemical homogeneity and reduced risk of segregation. In an embodiment the titanium-based alloy composition consists of 0.1 wt% or more hafnium. Such an alloy has improved wear resistance. In an embodiment, the titanium-based alloy composition consists of 0.0 to 0.2 % aluminium, 0.0 to 0.2 % vanadium, 0.0 to 0.2 % iron, 0.0 to 0.2 % chromium, 0.0 to 0.2% cobalt, 0.0 to 0.2 % nickel, 0.0 to 0.2% manganese. Such an alloy has improved biocompatibility. In an embodiment, in the titanium-based alloy composition the sum of wt % of each of aluminium, vanadium, iron, chromium, cobalt, nickel, manganese and boron is 1.0 wt. % or less, preferably 0.5wt% or less. Such an alloy has improved bio-compatibility. In an embodiment, the titanium-based alloy composition satisfies the following equation 0.0178Nb + 0.0143Mo + 0.0243Ta +0.0285Sn < 1.0 in which Mo, Nb, Ta, and Sn represent the amounts of molybdenum, niobium, tantalum and tin in wt% respectively. Such an alloy has a lower melting point leading to improved elemental homogeneity. In an embodiment, the titanium-based alloy composition satisfies the following equation 2.5 > 0.042Nb + 0.06Mo + 0.05Ta + 0.03Zr +0.1Snin which Mo, Nb, Ta, Zr and Sn represent the amounts of molybdenum, niobium, tantalum, zirconium and tin in wt% respectively. Such an alloy has a low solidification range meaning a reduced tendency to hot tear and re-melting of underlayers during laser additive manufacturing. In an embodiment, the titanium-based alloy composition satisfies the following equation [1.23*Ti(at)+1.01*Nb(at)+2.95*Mo(at)+1.86*Ta(at)+0.81*Zr(at)+0.50*Sn(at)]*[ 0.028*Nb(at)+1.412*Mo(at)+0.17*Ta(at)+0.832*Zr(at)+2.19*Sn(at)]^2 / 3>500 preferably [1.23*Ti(at)+1.01*Nb(at)+2.95*Mo(at)+1.86*Ta(at)+0.81*Zr(at)+0.50*Sn(at)]*[ 0.028*Nb(at)+1.412*Mo(at)+0.17*Ta(at)+0.832*Zr(at)+2.19*Sn(at)]^2 / 3>600 more preferably [1.23*Ti(at)+1.01*Nb(at)+2.95*Mo(at)+1.86*Ta(at)+0.81*Zr(at)+0.50*Sn(at)]*[ 0.028*Nb(at)+1.412*Mo(at)+0.17*Ta(at)+0.832*Zr(at)+2.19*Sn(at)]^2 / 3>650 more preferably [1.23*Ti(at)+1.01*Nb(at)+2.95*Mo(at)+1.86*Ta(at)+0.81*Zr(at)+0.50*Sn(at)]*[ 0.028*Nb(at)+1.412*Mo(at)+0.17*Ta(at)+0.832*Zr(at)+2.19*Sn(at)]^2 / 3>700 in which Ti, Mo, Nb, Ta, Zr and Sn represent the amounts of titanium, molybdenum, niobium, tantalum, zirconium and tin in wt% respectively. Such an alloy has increased strength. In an embodiment, the titanium-based alloy composition satisfies the following equation 3.5 ∗ ൬Fe wt. %+ Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % Nb wt. % 3.5 9+14+20+25+27+43 Zr Al preferably 3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % Nb wt. % 3.5 more preferably 3.5V wt. % W wt. % Sn wt. % Nb wt. % 20+25+27+43+Ta wt. %Zr wt. % Al wt. % 75 +90−18^ > 2.7more preferably3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % Nb wt. % 3.5 25+27+43 2.8more preferably 3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % Nb wt. % 3.5 25+27+43 2.9more preferably 3.5wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % Nb wt. % 3.5 25+27+43 3.0in which Fe, Cr, Mo, V, W, Al, Nb, Ta, Zr and Sn represent the amounts of iron, chromium, molybdenum, vanadium, tungsten, aluminium, niobium, tantalum, zirconium and tin in wt% respectively. Such an alloy has increased beta stability and thus reduced elasticity. In an embodiment, the titanium-based alloy composition satisfies the following equation % preferably 3.4 > 3.5wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % 3.5 +9+14+20+25+27 more preferably 3.3 > 3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % 3.5 +9+14+20+25+27 more preferably 3.2 > 3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % 3.5 +9+14+20+25+27 Nb wt. %Ta wt. % Zr wt. % Al wt. % in which Fe, Cr, Mo, V, W, Al, Nb, Ta, Zr and Sn represent the amounts of iron, chromium, molybdenum, vanadium, tungsten, aluminium, niobium, tantalum, zirconium and tin in wt% respectively. Such an alloy ensures superelasticity while still suppressing room-temperature stable martensite phase. In an embodiment, the titanium-based alloy composition satisfies the flowing relationship 1 1 3Sn wt. % +6Zr wt. % < 9.0preferably 1 1 3Sn wt. % +6Zr wt. % < 8.0more preferably 1 1 3Sn wt. % +6Zr wt. % < 7.0Such an alloy has improved ductility. In an embodiment, the titanium-based alloy composition satisfies the flowing relationship 2.79Ti(at. %)+3.099Nb(at. %)+3.063Mo(at. %)+3.144Ta(at. %)+3.086Zr(at. %)+2.283Sn(at. %) > 2.8 where Zr, Nb, Mo, Ta and Sn represent the amounts of zirconium, niobium, molybdenum, tantalum and tin respectively in at%. Such an alloy has improved bio-compatibility and low elastic modulus. The term “consisting of” is used herein to indicate that 100% of the composition is being referred to and the presence of additional components is excluded so that percentages add up to 100%. Unless otherwise stated, all amounts are in weight percent. The invention will be more fully described, by way of example only, with reference to the accompanying drawings in which: Figure 1 illustrates the biocompatibility of various alloying elements; Figure 2 is a flow diagram illustrating the process by which the titanium-based alloy composition was determined; Figure 3 illustrates the constrains used to isolate an alloy space with merit indices comparable to or better than the current alloys; Figure 4 illustrates the effect of Sn and Zr on the contour plots for the bond order of a few selected Ti-Nb-Ta systems; Figure 5 illustrates the effect of Sn and Zr on the contour plots for the strength of a few selected Ti-Nb-Ta systems; Figure 6 illustrates the effect of Sn and Zr on the contour plots for the martensite start temperature of a few selected Ti-Nb-Ta systems; Figure 7 illustrates the effect of Sn and Zr on the contour plots for the Fe equivalent of a few selected Ti-Nb-Ta systems; Figure 8 illustrates the effect of Sn and Zr on the contour plots for the Al equivalent of a few selected Ti-Nb-Ta systems; Figure 9 illustrates the optimal alloy space as constrained by the first 6 threshold equations as numbered in the top part of figure 10; Figure 10 illustrates the values of the threshold equations for each of the examples and baseline alloys; Traditionally, titanium-based alloys have been designed through empiricism. Thus, their chemical compositions have been isolated using time consuming and expensive experimental development, involving small-scale processing of limited quantities of material and subsequent characterisation of their behaviour. The alloy composition adopted is then the one found to display the best, or most desirable, combination of properties. The large number of possible alloying elements indicates that these alloys are not entirely optimised and that improved alloys are likely to exist. In titanium alloys, generally additions of aluminium (Al) are added as α- stabiliser to improve the mechanical strength. However, aluminium has been associated with neurological related diseases. For this reason the aluminium content is limited in this inventive alloy and alloys such as Ti6Al4V, Ti6Al7Nb and Ti15Mo 5Zr3Al are unsuitable for the present applications. General additions of vanadium (V) are added as β-stabiliser and to increase the mechanical strength without forming brittle intermetallic compounds. V makes a solid solution with the β phase. However, V is believed to have toxic and carcinogenic effects on the body. Additions of nickel (Ni), cobalt (Co), iron (Fe) and chromium (Cr) are also added as β-stabiliser elements. However, all of these are considered to have low bio-compatibility and are associated with adverse responses to body functions. Therefore, the alloy contains a maximum amount of 0.5% of each of Al, V, Ni, Co, Mn, Fe and Cr preferably 0.2% or less of each of Al, V, Ni, Co, Mn, Fe and Cr and a total sum of these elements and boron of 1.0% or less, preferably 0.5% or less. Calcium and carbon may be present at levels of up to 0.5% each and are not expected greatly to change the character of the alloy at this level. Oxygen, nitrogen and hydrogen may be present in the alloy at concentrations up to 0.5wt% each without reducing the characteristics of the alloy significantly. Oxygen will significantly improve the strength of the alloy but high amounts may have a negative effect on any shape memory effects that the alloy may exhibit. The same is true of gold, silver and palladium, each of which may be present in an amount of up to 0.5wt%. These may be added to increase bio-compatibility and to reduce infections. Lanthanum may be added in an amount up to 0.5wt.% in order to further improve the microstructure during solidification (similarly to B). Because the alloy is intended for use in an article to be placed in the human or animal body including prosthetic devices, orthopaedic implants, in particular bone implants and / or artificial joints, it is desirable to achieve the desired properties of the titanium alloy using mainly or even exclusively so-called “vital” elements which have been shown to have high biocompatibility and osseo- integration. Figure 1 is a graph showing the biocompatibility or otherwise of various possible alloying elements, obtained from Kuroda D, Niinomi M, Morinaga M, Kato Y, Yashiro T. Design and mechanical properties of new β type titanium alloys for implant materials. Materials Science and Engineering: A. 1998. In the alloy of the present invention, niobium (Nb) is used as β-stabiliser and to lower the elastic modulus of the alloy. Tantalum (Ta) can also also used as β- stabiliser and to promote bone growth into the metal. Zirconium (Zr) can be used as replacement of Ti further to reduce the elastic modulus – in combination with Nb and Ta, Zr can perform as β-stabiliser. Zr and Sn additions help lower the Ms temperature which in turn can further lower the elastic modulus of the alloy. In the present invention, molybdenum (Mo) can be used as a strong β- stabiliser to improve the strength and lower the stiffness. Although Mo is not a so- called ‘vital’ element, it has been shown that, when combined with Ti, it does not degrade the bio-compatibility of the alloy and that it has no adverse effects on the body – see Nunome et. al. In vitro evaluation of biocompatibility of Ti–Mo–Sn–Zr superelastic alloy, Journal of Biomaterials Applications, 2015. Tin (Sn) can be used to reduce the stiffness of the alloy, to add strength, and reduce Ms temperature. Because Sn has a very high lattice parameter and elastic misfit with respect to Ti, it is a very efficient element to solid solution strengthen Ti alloys. Moreover, due to recent discoveries that Sn in combination with Zr can reduce the Ms temperature (and thus β-stabilise the alloy), it allows Sn to act as a unique element to both increase strength and lower the stiffness. However, in large amounts combined with Zr, it can embrittle the alloy. Thus the combined amounts of Zr and Sn are preferably limited according to Sn / 3 + Zr / 6 < 9.0 wt. %, preferably < 8 wt. %, more preferably < 7 wt. %. In an embodiment at least 1.0% or more Sn is added to reduce stiffness and to increase strength. More preferably there is 3.5% or more tin, yet further to reduce stiffness and increase strength. It is assumed that Sn can replace Zr in the present invention. A minimum of 5.0 % tin is desirable for reduced stiffness and increased strength. Because Sn and Zr are key elements to increase the strength, in an embodiment of the invention, the titanium alloy satisfies the flowing equation 1 1 3.5 ≤ 3 Sn wt. % + 6Zr wt. %Where the minimum amount ensures good level of strength. Tin and Zr may be interchangeable and when present in an amount of 3.5% Al. eq. or more as illustrated by the above equation increase the strength of the alloy and reduce the overall stiffness while improving on bio-compatibility. Further increases in strength are possibly with alloys which have 4.0% Al. eq. or more or even 4.5% Al. eq. or more. The highest strength alloys have 5.0% Al. eq. or more, potentially at the expense of an increase in stiffness and increased risk of lower ductility. The limits in Figure 8 represents the following equation 1 1 3.5 ≤3 Sn wt. % +6Zr wt. % ≤ 8.0 Meeting this criterion ensures that the strength benefits of having enough aluminium equivalent elements is met while one avoids having low ductility caused by high Al equivalency. Hafnium (Hf) can optionally be used to increase the hardness of the alloy. However, Hf is a very expensive element and its used is restricted in the present invention to Hf ≤ 0.5 wt. %. For applications where high hardness (to improve wear resistance) is important, Hf can be present in an amount of 0.1% or more. A modelling-based approach used for the isolation of new grades of titanium- based bio-compatible alloys is described here, termed the “Alloys-By-Design” (ABD) method. This approach utilises a framework of computational materials models to estimate design relevant properties across a very broad compositional space. Figure 2 illustrates the various steps of the method. In principle, this alloy design tool allows the so-called inverse problem to be solved; identifying optimum alloy compositions that best satisfy a specified set of design constraints. The first step in the design process is the definition of an elemental list along with the associated upper and lower compositional limits. The compositional limits for each of the elemental additions considered in this invention – referred to as the “alloy design space” - are detailed in Table 2. Nb Mo Ta Zr Sn Min. 0.0 0.0 0.0 0.0 0.0 Max. 40.0 15.0 30.0 30.0 25.0 Table 2: Alloys design space in wt.% searched using the ‘Alloy-by-Design’ method. The second step relies upon thermodynamic calculations used to calculate the phase diagram and thermodynamic properties for a specific alloy composition. Often this is referred to as the CALPHAD method (CALculate PHAse Diagram). These calculations are conducted for those temperatures where an optimal phase architecture of the new alloy is found. A third stage involves isolating alloy compositions which have the desired microstructural architecture bio-medical purposes. In the bio-medical field, there is a need to design alloys that have low elastic modulus (to be close to that of the bone) and to use alloyants that improve bio-compatibility and osseo-integration. Metastable β alloys (BCC) have been shown to decrease substantially the elastic modulus when compared to α and β alloys (HCP + BCC). Moreover, the use of Nb, Zr, and Ta (all of them β stabilisers) is known to improve the bio-compatibility and osseo-integration of titanium alloys. Thus, it is desirable for the purposes here exposed to design a metastable β alloy employing the so-called ‘vital’ elements. Thus, the model isolates all compositions in the design space which are the most bio-compatible, which tend to form stable β microstructures for optimal additive manufacturability, and which have a high (tensile and compressive) strength and a low elastic modulus for good osseo-integration and reduced stress- shielding. Moreover, the important factors such as melting temperature and amount of alloyants – which are important to obtain a uniform and chemically homogeneous powder particle – are also weighted into the design process. In the fourth stage, merit indices are estimated for the remaining isolated alloy compositions in the dataset. Examples of these include: martensitic transformation merit index (which describes the temperature at which the transformation starts), elastic modulus and bone-growth compatibility (which are related to the bond order of the composition), manufacturability (which is related to the freezing range and the phase proportions of the alloy), strength (as modelled by aluminium equivalent and solid solution strengthening as a function of lattice parameter misfit and elastic misfit), and metal processability (which is related to the melting temperature, the solidification range, and the amount of titanium in the alloy). The first merit index is the bone-compatibility merit index, which highlights the speed at which cells grow into the metal interface. Okazaki and Tetsuya. (1998), Corrosion resistance, mechanical properties: corrosion fatigue strength and cytocompatibility of new Ti alloys without Al and V. Biomaterials, has shown that the bone-growth correlates with the bonding order of the alloy. Thus, the merit index is calculated using a rule of mixtures following where ^^^is the concentration of element i and Bo^the ith bonding order value of the element. Moreover, this merit index also measures the critical current density for passivation (which gives a measurement of the cytotoxicity) and an approximation to the elastic modulus of the alloy. Increasing the bonding order helps decreasing both the cytotoxicity and the elastic stiffness – see Brown SA, Lemons JE (1996) Medical Applications of Titanium and Its Alloys: The Material and Biological Issues. Table 3: Bonding order of each element. The second merit index relates to the susceptibility of the alloy to form the martensitic phase. This merit index uses an empirical relationship derived from experimental results including those reported by Endoh et. al. in Material Science & Engineering “Effect of Sn and Zr Content on Superelastic Properties of Ti-Mo-Sn- Zr Biomedical Alloys” Materials Science & Engineering A (2017) and those reported in M. Bignon, E. Bertrand and F. Tancret et al. “Modelling martensitic transformation in titanium alloys: The influence of temperature and deformation” Materialia (2019). The martensitic start temperature (in K) is calculated as a function of the alloy composition following 14.7 ∗ ^^ ^^ + 0.28 ∗ ^^ ^^ ∗ ^^ ^^ + 1.2 ∗ ^^ ^^ଶ+ 0.14 ∗ ^^ ^^ଶ− 225 − 8.88 ∗ ^^ ^^ − 0.68 ∗ ^^ ^^ ∗ ^^ ^^ − 0.0058 ∗ ^^ ^^ ∗ ^^ ^^ଶIf the martensitic start temperature is below ambient temperature, martensitic phase will not be present at the microstructure level. Martensitic temperature is a useful predictor of the stiffness in titanium alloys, and it allows to define regions within which superelasticity is most likely (those where Ms is close to ambient temperature). The third merit index is the freezing range. The freezing range is effectively the temperature range of the two-phase liquid + β phase region. This merit index is calculated using the Scheil thermodynamic calculation in ThermoCalc and provides the transient solidification route of the alloy. An expanded solidification range has the potential to increase hot tearing and remelting of underneath layers during laser manufacturing as well as segregation during solidification of the alloy during processing or manufacturing. Thus, it is desirable to monitor the temperature range at which the transition from liquid to solid occurs. Although not the most critical factor, it is desirable to minimise the solidification range. The solidifaction range of the alloy is approximated as a function of the mean chemistry following the method developed in WO2019 / 166749 as follows: Solidification range index = 0.042Nb + 0.06Mo + 0.05Ta + 0.03Zr +0.1Sn. In an embodiment, to ensure good processibility, the non-dimension solidification range index should take value 2.5 or lower. The fourth merit index is a strength merit index which considers solid solution strengthening as a function of lattice parameter misfit and shear modulus misfit. This model is shown in Zhao in “Modelling Strengthening Mechanisms In Beta-Type Ti Alloys”, Material Science and Engineering A 756(2019) 156-160 to be reliable for Beta-phase alloys such as those of the present invention. This solid solution strength is calculated following where Bସ / ୧ = Mµλଷ୧ Z is a parameter function of the misfit parameter accounting for the solute / solvent lattice parameter misfit and the shear modulus misfit. M is the Taylor factor, λ is a misfit parameter accounting for the solute / solvent lattice parameter misfit, μ is the shear modulus of the alloy, Z is a material parameter adopted as 0.9x10-3in the literature. Xiis the atomic fraction of each element in the alloy. Specific parameters for each element can be found in in Zhao in “Modelling Strengthening Mechanisms In Beta-Type Ti Alloys”, Material Science and Engineering A 756(2019) 156-160. For convenience, the strength model is here fully developed for the elements / compositions of interest. The following relationship between strength (MPa) and composition was established: ^^^^ ^^=[1.23*Ti(at)+1.01*Nb(at)+2.95*Mo(at)+1.86*Ta(at)+0.81*Zr(at)+0.50*Sn(a t)]*[0.028*Nb(at)+1.412*Mo(at)+0.17*Ta(at)+0.832*Zr(at)+2.19*Sn(at)]^2 / 3 To ensure a good level of strength, preferably the fourth merit index limits the optimal design compositions to levels of ^^^^ ^^above 500 MPa, more desirably above 600 MPa. The fifth merit index in the Fe eq. of the alloy. This quantity correlates to the beta-stability of the alloy. The suggested criterion uses Fe as a reference element because it has the strongest stabilizing effect on the ^^ phase. The proposed Fe eq. merit is proposed as follows: where the coefficient to each term is obtained by dividing the critical concentration of Fe necessary to retain ^^ at room temperature – and thus the likelihood of ^^ remaining after deformation. For simplicity, in the remaining of this document, the Fe eq. expression is simplified to the main elements of interest following: [ ^^ ^^]^^ ^^= 3.5 ∗ (Nb / 43 + Mo / 14 + Ta / 75 + Zr / 90 + Sn / 27) However, the full expression still applies in case other elements are added to the alloy (even in amounts < 0.5 wt. %). To lower the effective elastic modulus of the alloy (stiffness) one desires the appearance of martensite phase during deformation and loading (this is called superelasticity). This can only occur when: (i) Fe eq. is 3.5 wt. % or below, and (ii) Ms temperature is below 450 K, more desirably below 350 K. Thus, this merit index desirably limits the maximum Fe eq. to 3.5 wt. %. A minimum amount of Fe eq. is used so that most of the phase structure is formed by ^^ upon rapid cooling. Thus, the Fe eq. is set at 2.0 or more. With values of Fe eq. 2.5 wt. % and above, it can be ensured that most of the phase structure is formed by ^^ by upon rapid cooling, thus this limit is preferably imposed on the design alloys. The sixth merit index is the metal processability. To facilitate the powder production process and obtain optimal elemental homogenisation, the melting temperature and the amount of alloyants must be minimised. Thus, for the sixth index, the temperature of the melting point is calculated, this is desirably below 1900°C. The melting point can be approximated as a non-dimensional quantity as a function of the mean chemistry following Melting index = 0.0178Nb + 0.0143Mo + 0.0243Ta +0.0285Sn. This relationship was developed in WO2019 / 166749. In order to ensure low enough melting point, the melting index should be below 1. The sixth merit index also limits the amount of alloyants. Preferably pure titanium is at least 50.0 wt. % of the final composition. It is thought that it is desirable to maintain titanium in at least an amount of 52.5 wt. %, preferably at least 55.0 wt.% of the final composition to ease powder processing. The ABD method described above was used to isolate the inventive alloy composition. The design intent for this alloy was to isolate the composition of a new titanium alloy which exhibits a combination of stiffness, strength, manufacturability, processability, cytotoxity, and osseo-integration which is comparable or better than equivalent grades of alloy. The cost of the alloy has also been considered in the design of the new alloy. The cost is based on the amount of each element contained in the alloy at 2018 prices. The material properties – determined using the ABD method – for the literature titanium alloys are listed in Table 4. The design of the new alloy was considered in relation to the predicted properties listed for these alloys. The method was used to propose twenty optimised alloy compositions which target different properties. The calculated material properties for the optimised alloys with nominal compositions according to Table 4 and in accordance with the present invention are also given. Examples 1-7 are most preferred. These alloys have less than the maximum allowable amount of niobium (e.g. 19.5wt% or less) and tin (e.g. 19.0wt% or tin) and a Fe eq above 2.5, all of which are particularly desirable, as described elsewhere.
[0003] Table 4: Calculated phase fractions and merit indices made with the “Alloys-by-Design” software. Results for prior art Ti alloys as listed in Table 1 and the nominal composition of the new alloys. Figure 5 shows that Zr and Sn have a very positive influence on strength while Nb shows a very neutral effect on strength. Only areas where Ti is present at a level of 50wt% or more is plotted (same in figs. 6-9). However, Nb has a very strong influence on the martensite start temperature, the bond order, and the Fe equivalent. That means that optimally one wants to add just enough Nb to achieve optimal values of Ms, bond order, and Fe equivalent, but also limit its presence due to the neutral effect on strength – i.e. after reaching the required level of Ms, one wants to leave as much space as possible to elements like Sn and Zr that greatly increase the strength. For this reason, the presence of Nb is limited to 22.5 wt. % or less. By further reducing the maximum amount of Nb, Figure 9 shows that higher strength values are achievable while still meeting the Fe eq, Ms, and Bo targets. Thus, an upper limit of 20 wt. % is preferrable, and an upper limit of 19.5wt% or 19.0wt% is more preferable still. An upper limit of 17.5 wt. % niobium is more preferable, and an upper limit of 16.5 wt. % is the most preferable increasing its strength and ease of manufacture of the starting powder. Niobium is an optional addition. However, preferably niobium is added in an amount of at least 1.5 wt.% so as to increase beta-stability and help reduce Ms temperature and a high enough Fe equivalent and bone compatibility. In a preferred embodiment, niobium is added in an amount of at least 2.0% or even 3.0% or 5.5 wt. %. According to Figure 9, increasing the amount of Nb will allow one to achieve lower Ms, higher Bo, and higher Fe equivalent without triggering the Al equivalent limit which occurs when replacing all the Nb with Sn and Zr (desirable for strength, but a very high Al equivalent increases risk of brittle behaviour). Sn exhibits a direct trade-off between increasing strength, increasing Fe equivalency, (desirable) and increasing brittleness (undesirable – which is proportional to the increase in Al equivalency). Moreover, large amounts of tin tend to lower the bond order of the alloy – Figure 4 shows that for the preferred alloy space, large amounts of tin tend to produce a value of bond order which is too low. Moreover, Figure 8 shows that large amounts of Sn also lead to high Al equivalency (thus higher risk of brittle behaviour). Thus, an upper limit for Tin is imposed at Sn=20.0wt%. Preferably, tin is present in amounts lower than 19.0wt% or 18.0wt% or even 17.0wt%. More preferably, lower than 16.0%. Most preferably lower than 15.0 in order to lower Al equivalency and increase the bond order. In a preferred embodiment, the amount of tin is 13.0 wt.% or less in order to avoid a significant decrease of the bond order and to reduce the likelihood of brittleness. Nonetheless, addition of tin can significantly increase the strength while also decreasing Ms temperature and increasing Fe equivalency – all of these very desirable. Thus, in a preferred embodiment, the amount of tin is 2.0 wt.% or more to add strength and to lower the stiffness but more importantly to increase Fe equivalency and lower Ms temperature. Preferably tin is present in amount of 3.0% or larger. More preferably in an amount of 5.0% or larger. As can be seen from the contour plots of the bond order in Figure 4, tantalum has a strong influence on advantageously increasing the bond order. This promotes cell growth and indicates decreased toxicity. Ta also increases Fe equivalency (Figure 7) and lowers the Ms temperature (Figure 6) to achieve optimal elasticity. On the other hand, tantalum is deleterious in terms of reduced strength (Figure 5). An upper limit of 15.0% Ta is set in order to maintain a sufficiently high strength. Desirably the maximum amount of tantalum is 13.5% or less as this can help in the manufacturability of the atomised alloy (because this allows a higher amount of titanium so that the possibility of segregation during atomisation is reduced and lower melting point). Due to the deleterious effect on strength, the preferable limit is below 12%, more preferably below 10.5%. However, Ta has a positive effect increasing Fe equivalency, increasing bond order, and slightly reducing the Ms temperature. To achieve a bond order which is comparable with the best performing existing alloys shown in Table 1, the amount of tantalum is preferably 1.0% or more, more preferably 2.0% or more. To help further increasing Fe equivalency and lowering Ms without needing to add further Zr and Sn (which can cause brittle behaviour), Ta is desirable in amounts of at least 2.5%. However, tantalum may be absent, depending upon the combination of properties desired. Molybdenum can have a very strong effect on reducing the martensitic start temperature and increasing Fe equivalency, thus β-stabilising the alloy while keeping the content of pure titanium high. Molybdenum can also be important in increasing the strength of the alloy. Molybdenum can exhibit a similar beta-stability effect to Nb but at smaller quantities. However, Nb offers superior biocompativility. For this reason, the current invention considers the potential replacement of Nb with Mo as a beta-stabilising element on the alloy but at restricted amounts. Therefore, a suitable level of molybdenum is 5.0 wt.% or less. Levels of molybdenum of 3.0% or less or even 1.0% or less are even more desirable for the same reason. Similarly to Sn, Zr exhibits a direct trade-off between: (i) increasing strength, increasing bond order, slightly increasing Fe equivalency, and slightly decreasing Ms temperature (all desirable for increased strength, biocompatibility, and reduced stiffness respectively), and (ii) increasing Al equivalency and thus the risk of brittle behaviour. Figure 5 shows the strong effect of Zr in increasing the strength. Thus, this invention aims to maximise the amount of Zr, preferably while ensuring that the combined levels of Zr and Sn don’t cause brittle behaviour (for example by using Al equivalency as a proxy). Zr is also known to substitute for Ti while adding bio- compatibility. Moreover, Zr is known to lower the stiffness (it substantially increases bonding order – see Figure 4). With the above in mind, a minimum amount of 1.5% or more is desirable in order to increase the bond order, to add strength, to lower Ms temperature, and to add beta-stability (see Fe equivalency graphs). More preferably 3.0% or more or 4.5% or more further to increase the strength. Zr is a desirable element. To keep sufficient ductility, the suitable maximum amount of zirconium is 22.0wt% or less, preferably 20.0% or less. In order to ensure high elongation, Zr can be limited to 18% or less, more preferably 16% or less or even 15.0% or less. Limiting the amount of Zr also ensures a high Ti content. Figure 9 is a summary of the preferable requirements of the alloy together with a series of linearised restrictions which were derived to isolate the optimal alloy space. Figure 10 is a table for compositions falling within the preferred range and is simply used to illustrate further restrictions on the alloy which result in the best combination of the first-sixth merit indices. Regression analysis was performed on the results of some of the calculations of the merit indices to determine the following relationships which are valid within the elemental range of the alloy (Nb 0-30, Mo 0-7.5, Ta 0-20.0, Zr 0-25.0 and Sn 0- 20.0). The first merit index is desirably an alloy with a bonding order of greater than 2.85. This requirement is met by an alloy satisfying the following equation (equation 5) 2.79Ti(at.%)+3.099Nb(at.%)+3.063Mo(at.%)+3.144Ta(at.%)+3.086Zr(at.%)+2.283Sn(a t.%) > 2.8 where Zr, Nb, Mo, Ta and Sn represent the amounts of zirconium, niobium, molybdenum, tantalum and tin respectively in at%. Such an alloy has a bonding order comparable to that of prior art alloys as shown in Table 1. This equation is illustrated in the limits of Figure 4. These alloys have high enough bond order for improved bio-compatibility and low elastic modulus. The second merit index, namely the susceptibility to martensitic phase is already described above with respect to the equation for MS. The limit in Figure 6 mark the maximum and minimum desired martensitic start temperature (450K and 200K). The equation is approximated as follows: 200<14.7*Ti+0.28*Nb*Sn+1.2*Sn^2+0.14*Zr^2-225-8.88*Nb-0.68*Sn*Ti- 0.0058*Zr*Nb^2<450. A higher martensitic start temperature of 250K or above is more desirable, and a martensitic start temperature of 300K or above is also desirable. A martensitic start temperature of 400K or lower or even 350K or lower is desirable as this reduces stiffness. The strength merit index is formulated as follows: [1.23*Ti(at)+1.01*Nb(at)+2.95*Mo(at)+1.86*Ta(at)+0.81*Zr(at)+0.50*Sn(at)]*[0.028* Nb(at)+1.412*Mo(at)+0.17*Ta(at)+0.832*Zr(at)+2.19*Sn(at)]^2 / 3>500 The preferred limits for strength are visualised in Figure 5. This ensures good level of strength in the alloy. As shown in figure 10, some alloys of the invention have a strength merit index of 650MPa or more and this is desirable. Some alloys of the invention have a strength merit index of 700MPa or more and this is also desirable. The Fe equivalency index can be approximated as follows because the amounts of iron, chromium, vanadium, tungsten and aluminium are limited in the present invention: 3.5>3.5*(Nb / 43+Mo / 14+Ta / 75+Zr / 90+Sn / 27)>2.5 The preferred limits for Fe equivalency are visualised in Figure 7. The lower limit ensures that the alloy is enough beta-stabilised to lower the elastic modulus while the upper limit ensures that the ‘superleastic’ effect is not lost by fully suppressing martensitic transformations. The lower limit can be increased to 2.5, 2.6, 2.7, 2.8 or 2.9 or even 3.0, resulting in increased beta stability. The upper limit can be reduced to 3.5, 3.4, 3.3 or even 3.2, ensuring superelasticity and supressing martensitic transformation. In an embodiment those upper and lower limits are applied to the equation for [ ^^ ^^]^^ ^^given above when the fifth merit index is introduced. The amounts of silicon and boron are not arrived at from thermodynamic calculations but instead are added from knowledge that they will increase strength and creep resistance and enhance ductility of the alloy. As such, they are allowable up to 0.2 wt% boron and 1.0 wt% silicon.
Claims
Claims 1. A titanium-based alloy composition consisting in weight percent, of: 0.0 to 22.5 % niobium, 0.0 to 5.0 % molybdenum, 0.0 to 15.0% tantalum, 0 to 22.0% zirconium, 0 to 20.0% tin, 0.0 to 0.5% hafnium, 0.0 to 0.5 % aluminium, 0.0 to 0.5 % vanadium, 0.0 to 0.5 % iron, 0.0 to 0.5 % chromium, 0.0 to 0.5% cobalt, 0.0 to 0.5 % nickel, 0.0 to 1.0% silicon, 0.0 to 0.2% boron, 0.0 to 0.5% calcium, 0.0 to 0.5% carbon, 0.0 to 0.5% manganese, 0.0 to 0.5% gold, 0.0 to 0.5% silver, 0.0 to 0.5% oxygen, 0.0 to 0.5% hydrogen, 0.0 to 0.5% nitrogen, 0.0 to 0.5% palladium, 0.0 to 0.5% lanthanum, the balance being titanium and incidental impurities, wherein the composition satisfies the following equations: ^ ^ ଷ Sn wt. % +^Zr wt. % > 3.5 , and; 3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % Nb wt. % 3.5 +9 25+27+43 +Ta wt. %752.0in which Fe, Cr, Mo, V, W, Al, Nb, Ta, Zr and Sn represent the amounts of iron, chromium, molybdenum, vanadium, tungsten, aluminium, niobium, tantalum, zirconium and tin in wt% respectively.
2. The titanium-based alloy composition of claim 1, consisting of 3.0% or less molybdenum, preferably 1.0 or less molybdenum.
3. The titanium-based alloy composition of any of claims 1 to 2, consisting of 19.0% or less tin, preferably 18.0% or less tin, preferably 17.0% or less tin, preferably 16.0% or less tin, more preferably 15.0% or less tin, most preferably 13.0% or less.
4. The titanium-based alloy composition of any of claims 1 to 3, consisting of 1.0% or more tin, preferably 2.0% or more tin, more preferably 3.0 or more or 3.5% or more tin, most preferably 5.0% or more tin.
5. The titanium-based alloy composition of any of claims 1 to 4, consisting of 20.0% or less zirconium, preferably 18.0% or less zirconium, more preferably 16.0% or less zirconium, even more preferably 15.0% or less zirconium.
6. The titanium-based alloy composition of any of claims 1 to 5, consisting of 1.5% or more zirconium, preferably 3.0% or more zirconium, more preferably 4.5% or more zirconium 7. The titanium-based alloy composition of any of claims 1 to 6, which satisfies the flowing relationship 1 1 3Sn wt. % +6Zr wt. % > 4.0preferably 1 1 3Sn wt. % +6Zr wt. % > 4.5more preferably 1 1 3Sn wt. % +6Zr wt. % > 5.0in which Al, Sn and Zr represent the amounts of aluminium, tin and zirconium in wt% respectively.
8. The titanium-based alloy composition of any of claims 1 to 7, consisting of 1.5% or more niobium, preferably 2.0% or more niobium, more preferably 3.0% or more niobium, most preferably 5.5% or more niobium.
9. The titanium-based alloy composition of any of claims 1 to 8, consisting of 20.0% or less niobium, preferably 19.5% or less niobium, more preferably 19.0% or less niobium, more preferably 17.5% or less niobium, more preferably 16.5% or less niobium.
10. The titanium-based alloy composition of any of claims 1 to 9, consisting of 13.5% or less tantalum, preferably 12.0% or less tantalum, more preferably 10.5% or less tantalum.
11. The titanium-based alloy composition of any of claims 1 to 10, consisting of 1.0% or more tantalum, preferably 2.0% or more tantalum, more preferably 2.5% or more tantalum.
12. The titanium-based alloy composition of any of claims 1 to 11, which satisfies the flowing equation 200 < 14.7 ∗ ^^ ^^ + 0.28 ∗ ^^ ^^ ∗ ^^ ^^ + 1.2 ∗ ^^ ^^^2 + 0.14 ∗ ^^ ^^^2 − 225 − 8.88 ∗ ^^ ^^ − 0.68 ∗ ^^ ^^ ∗ ^^ ^^ − 0.0058 ∗ ^^ ^^ ∗ ^^ ^^^2 preferably 250 < 14.7 ∗ ^^ ^^ + 0.28 ∗ ^^ ^^ ∗ ^^ ^^ + 1.2 ∗ ^^ ^^^2 + 0.14 ∗ ^^ ^^^2 − 225 − 8.88 ∗ ^^ ^^ − 0.68 ∗ ^^ ^^ ∗ ^^ ^^ − 0.0058 ∗ ^^ ^^ ∗ ^^ ^^^2, more preferably 300 < 14.7 ∗ ^^ ^^ + 0.28 ∗ ^^ ^^ ∗ ^^ ^^ + 1.2 ∗ ^^ ^^^2 + 0.14 ∗ ^^ ^^^2 − 225 − 8.88 ∗ ^^ ^^ − 0.68 ∗ ^^ ^^ ∗ ^^ ^^ − 0.0058 ∗ ^^ ^^ ∗ ^^ ^^^2, in which Fe, Cr, Mo, V, Nb, Ta, Zr, Sn and Al represent the amounts of iron, chromium, molybdenum, vanadium, niobium, tantalum, zirconium, tin and aluminium in wt% respectively.
13. The titanium-based alloy composition of any of claims 1 to 12, which satisfies the flowing equation 14.7*Ti + 0.28*Nb*Sn+1.2*Sn^2+0.14*Zr^2-225-8.88*Nb-0.68*Sn*Ti- 0.0058*Zr*Nb^2<450 preferably 14.7*Ti + 0.28*Nb*Sn+1.2*Sn^2+0.14*Zr^2-225-8.88*Nb-0.68*Sn*Ti- 0.0058*Zr*Nb^2<350 in which Fe, Cr, Mo, V, Nb, Ta, Zr, Sn and Al represent the amounts of iron, chromium, molybdenum, vanadium, niobium, tantalum, zirconium, tin and aluminium in wt% respectively.
14. The titanium-based alloy composition of any of claims 1 to 13, consisting of 50.0 wt% or more titanium preferably 52.5 wt% or more titanium, more preferably 55.0 wt% or more titanium.
15. The titanium-based alloy composition of any of claims 1 to 14, which satisfies the following equation1 1 3Sn wt. % +6Zr wt. % < 9.0preferably 1 1 3Sn wt. % +6Zr wt. % < 8.0more preferably 1 1 3 Sn wt. % + 6Zr wt. % < 7.0in which Al, Sn and Zr represent the amounts of aluminium, tin and zirconium in wt% respectively.
16. The titanium-based alloy composition of any of claims 1 to 15, consisting of 0.1 wt% or more hafnium.
17. The titanium-based alloy composition of any of claims 1 to 16, consisting 0.0 to 0.2 % aluminium, 0.0 to 0.2 % vanadium, 0.0 to 0.2 % iron, 0.0 to 0.2 % chromium, 0.0 to 0.2% cobalt, 0.0 to 0.2 % nickel, 0.0 to 0.2% manganese.
18. The titanium-based alloy composition of any of claims 1 to 17, wherein the sum of wt % of each of aluminium, vanadium, iron, chromium, cobalt, nickel, manganese and boron is 1.0 wt. % or less, preferably 0.5wt% or less.
19. The titanium-based alloy composition of any of claims 1 to 18, which satisfies the following equation 0.0178Nb + 0.0143Mo + 0.0243Ta +0.0285Sn < 1.0 in which Mo, Nb, Ta, and Sn represent the amounts of molybdenum, niobium, tantalum and tin in wt% respectively.
20. The titanium-based alloy composition of any of claims 1 to 19, which satisfies the following equation 2.5 > 0.042Nb + 0.06Mo + 0.05Ta + 0.03Zr +0.1Sn in which Mo, Nb, Ta, Zr and Sn represent the amounts of molybdenum, niobium, tantalum, zirconium and tin in wt% respectively.
21. The titanium-based alloy composition of any of claims 1 to 20, which satisfies the following equation [1.23*Ti(at)+1.01*Nb(at)+2.95*Mo(at)+1.86*Ta(at)+0.81*Zr(at)+0.50*Sn(at)]*[ 0.028*Nb(at)+1.412*Mo(at)+0.17*Ta(at)+0.832*Zr(at)+2.19*Sn(at)]^2 / 3>500 preferably [1.23*Ti(at)+1.01*Nb(at)+2.95*Mo(at)+1.86*Ta(at)+0.81*Zr(at)+0.50*Sn(at)]*[ 0.028*Nb(at)+1.412*Mo(at)+0.17*Ta(at)+0.832*Zr(at)+2.19*Sn(at)]^2 / 3>600 more preferably [1.23*Ti(at)+1.01*Nb(at)+2.95*Mo(at)+1.86*Ta(at)+0.81*Zr(at)+0.50*Sn(at)]*[ 0.028*Nb(at)+1.412*Mo(at)+0.17*Ta(at)+0.832*Zr(at)+2.19*Sn(at)]^2 / 3>650 more preferably [1.23*Ti(at)+1.01*Nb(at)+2.95*Mo(at)+1.86*Ta(at)+0.81*Zr(at)+0.50*Sn(at)]*[ 0.028*Nb(at)+1.412*Mo(at)+0.17*Ta(at)+0.832*Zr(at)+2.19*Sn(at)]^2 / 3>700 in which Ti, Mo, Nb, Ta, Zr and Sn represent the amounts of titanium, molybdenum, niobium, tantalum, zirconium and tin in wt% respectively.
22. The titanium-based alloy composition of any of claims 1 to 21, which satisfies the following equationmore preferably3Nb wt. %more preferably Nb wt. %in which Fe, Cr, Mo, V, W, Al, Nb, Ta, Zr and Sn represent the amounts of iron, chromium, molybdenum, vanadium, tungsten, aluminium, niobium, tantalum, zirconium and tin in wt% respectively.
23. The titanium-based alloy composition of any of claims 1 to 22, which satisfies the following equation 3.5 > 3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % 3.5 +9+14+20+25+preferably 3.4 > 3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % 3.5 +9+14+20+25+more preferably 3.3 > 3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt 3.5 +. % 9+14+20+25+27more preferably 3.2 > 3.5 ∗ ൬Fe wt. %Cr wt. % Mo wt. % V wt. % W wt. % Sn wt. % 3.5 +9+14+20+25+27in which Fe, Cr, Mo, V, W, Al, Nb, Ta, Zr and Sn represent the amounts of iron, chromium, molybdenum, vanadium, tungsten, aluminium, niobium, tantalum, zirconium and tin in wt% respectively.
24. The titanium-based alloy composition of any of claims 1 to 23, which satisfies the flowing relationship 2.79Ti(at. %)+3.099Nb(at. %)+3.063Mo(at. %)+3.144Ta(at. %)+3.086Zr(at. %)+2.283Sn(at. %) > 2.8 where Zr, Nb, Mo, Ta and Sn represent the amounts of zirconium, niobium, molybdenum, tantalum and tin respectively in at%.
25. An implant or prosthetic device made of the titanium-based alloy composition of any of claims 1-24.
26. A method of additive manufacturing an article which uses the titanium- based alloy composition of any of claims 1-24.
27. The method of claim 26, wherein the article is an implant or prosthetic device.
Citation Information
Patent Citations
Titanium alloy and hard tissular substitutive material using same
JP1998219375A
Substitute material for hard tissue
JP2000102602A
Surgical implant and alloy for use in making an implant
US4040129A
Process for manufacturing a titanium niobium zirconium (TNZ) beta-alloy with a very low modulus of elasticity for biomedical applications and method for producing same by additive manufacturing
WO2017137671A1
A bio-compatible titanium alloy optimised for additive manufacturing
WO2019166749A1
